Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma

Completed · Phase 2

Conditions studied: Ovarian Cancer, Sarcoma

In brief

Phase II trial to study the effectiveness of dolastatin 10 in treating patients who have recurrent or metastatic soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Key facts

Study ID

NCT00003778

Run by

National Cancer Institute (NCI)

People needed

37

Starts

1999-04-01

Last updated by the study team

2013-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Cancer Center — Denver, Colorado, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.